A number of firms have modified their ratings and price targets on shares of Kura Oncology (NASDAQ: KURA) recently:

  • 9/9/2017 – Kura Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
  • 9/8/2017 – Kura Oncology was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 9/7/2017 – Kura Oncology is now covered by analysts at Cowen and Company. They set an “outperform” rating on the stock.
  • 9/6/2017 – Kura Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
  • 9/1/2017 – Kura Oncology was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/29/2017 – Kura Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
  • 8/23/2017 – Kura Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. They now have a $7.25 price target on the stock. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
  • 8/10/2017 – Kura Oncology had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $18.00 price target on the stock, up previously from $16.00.
  • 8/10/2017 – Kura Oncology was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
  • 8/8/2017 – Kura Oncology was given a new $13.00 price target on by analysts at Citigroup Inc.. They now have a “buy” rating on the stock.
  • 7/18/2017 – Kura Oncology was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Shares of Kura Oncology, Inc. (NASDAQ KURA) traded up 13.751% during midday trading on Thursday, reaching $13.252. The company’s stock had a trading volume of 1,103,288 shares. The company’s market cap is $264.88 million. Kura Oncology, Inc. has a 12 month low of $4.00 and a 12 month high of $13.80. The company’s 50-day moving average price is $8.09 and its 200-day moving average price is $8.81.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.03. On average, equities analysts anticipate that Kura Oncology, Inc. will post ($1.53) EPS for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Receive News & Ratings for Kura Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.